Use of biologic agents in rheumatoid arthritis: a bibliographic review
Uso de imunobiológicos na artrite reumatoide: uma revisão bibliográfica
DOI:
https://doi.org/10.53660/CLM-3574-24L10Palavras-chave:
Drug Therapy, Methotrexate, Monoclonal AntibodiesResumo
Rheumatoid Arthritis (RA) is an autoimmune and chronic disease, which presents a heterogeneity of clinical manifestations and high potential for disability, consequently leading to a difficult diagnosis and treatment by health professionals. Common symptoms are pain, swelling, tenderness, warmth and redness in the affected joints, with long-term joint destruction, demonstrating the importance of early diagnosis and rapid initiation of treatment to prevent and control the pathogenic activity of the disease. Pharmacological treatment aims to mitigate and prevent joint damage, in addition to improving the patient's quality of life. Drug therapy varies according to the clinical stage and is based on the use of analgesics, corticosteroids, disease-modifying drugs, immunosuppressants and biologic agents. This article aims to address the treatment of RA, focusing on the use of biologic and targeted synthetic response modifiers and the best therapeutic choice, based on an integrative review with a survey of scientific data from 2017 to 2022, through guiding questions, based on of health data. The expected results include a synthetic and complete study of the treatment of RA and a thorough data analysis that in fact allows a better choice in the treatment of the disease.
Downloads
Referências
ARNETT, Frank. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, v. 31, n. 3, p. 315-324, 1988.
BONFIGLIOLI, Karina Rossi et al. Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis. Advances in Rheumatology, v. 61, 2021.
BRASIL. Ministério da Saúde. Secretaria de Atenção Especializada à Saúde. Secretaria De Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. Portaria Conjunta N. º 6, de 03 de Setembro de 2021. Aprova O Protocolo Clínico e Diretrizes Terapêuticas da Artrite Reumatoide e Artrite Idiopática Juvenil. 2021. Disponível em: <https://as1.trt3.jus.br/bd-trt3/handle/11103/68826> Acesso em: 25/05/2022.
BURMESTER, Gerd. et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Annals of the rheumatic diseases, v. 76, n. 5, p. 840-847, 2017.
BURMESTER, Gerd. et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the rheumatic diseases, v. 75, n. 6, p. 1081-1091, 2016.
CARVALHO, Marco Antonio P.; LANNA, Cristina Costa Duarte; BÉRTOLO, Manoel Barros. Reumatología: Diagnóstico E Tratamento . Grupo Gen-Guanabara Koogan, 2000.
FALCÃO, Jansen Giesen. Estratégias de troca para segundo imunobiológico na artrite reumatoide: resultados do registro brasileiro de agentes imunobiológicos em doenças reumáticas - BIOBADABRASIL. 2017. 93 f. Dissertação (Mestrado em Medicina) - Universidade Federal do Espírito Santo, Vitória, 2017.
FIRESTEIN, Gary S. Evolving concepts of rheumatoid arthritis. Nature, v. 423, n. 6937, p. 356-361, 2003.
FLEISCHMANN, Roy et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease‐modifying antirheumatic drug treatment. Arthritis & Rheumatology, v. 69, n. 3, p. 506-517, 2017.
FLEISCHMANN, Roy. et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Annals of the rheumatic diseases, v. 78, n. 11, p. 1454-1462, 2019.
GENOVESE, Mark. et al. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis research & therapy, v. 22, n. 1, p. 1-17, 2020.
GOELDNER, Isabela et al. Artrite reumatoide: uma visão atual. Jornal Brasileiro de Patologia e Medicina Laboratorial, v. 47, p. 495-503, 2011.
GUO, Qiang et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone research, v. 6, n. 1, p. 1-14, 2018.
HARRIS JR, Edward. Rheumatoid arthritis: pathophysiology and implications for therapy. New England Journal of Medicine, v. 322, n. 18, p. 1277-1289, 1990.
HETLAND, Merete Lund et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ, v. 371, 2020.
LAURINDO, Iêda Maria Magalhães et al. Artrite reumatóide: diagnóstico e tratamento. Revista Brasileira de Reumatologia, v. 44, p. 435-442, 2004.
MACHOLD, Kenned et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology, v. 46, n. 2, p. 342-349, 2007.
MANDAL, Ananya. Epidemiologia da artrite reumatoide. News-Medical. Disponível em: <https://www.news-medical.net/health/Rheumatoid-Arthritis-Epidemiology.aspx>. Acesso em: 25/05/2022.
MCINNES, Iain.; SCHETT, Georg. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine, v. 365, n. 23, p. 2205-2219, 2011.
MOTA, Licia Maria Henrique da et al. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis. Advances in Rheumatology, v. 58, 2019.
MOTA, Licia Maria Henrique da et al. Segurança do uso de terapias biológicas para o tratamento de artrite reumatoide e espondiloartrites. Revista brasileira de reumatologia, v. 55, p. 281-309, 2015.
SHINJO, Samuel Katsuyuki; MOREIRA, Caio (Ed.). Livro da sociedade brasileira de reumatologia.- 2 ed. Barueri : Manole, 2021. 888 .p.
SMOLEN, Josef. et al. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. Rheumatology, v. 60, n. 5, p. 2256-2266, 2021.
SOCIEDADE BRASILEIRA DE REUMATOLOGIA. Comitê Científico Biobadabrasil. Registro brasileiro de monitorização de terapias biológicas em doenças reumáticas, protocolo, versão 1.0, agosto de 2008.
STAMM, Tanja Alexandra et al. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. Arthritis Research & Therapy, v. 20, n. 1, p. 1-12, 2018.
STRAND, Vibeke et al. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD open, v. 5, n. 2, p. e001040, 2019.
TAYLOR, Peter. et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. New England Journal of Medicine, v. 376, n. 7, p. 652-662, 2017.
TORNERO-MOLINA, Jesús et al. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. Reumatología Clínica (English Edition), v. 18, n. 1, p. 33-41, 2022.
VAN DER LINDEN, Michale. et al. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis & Rheumatism, v. 63, n. 1, p. 37-42, 2011.
VAN VOLLENHOVEN, Ronald. et al. Tofacitinib in rheumatoid arthritis: lack of early change in disease activity and the probability of achieving low disease activity at month 6. Arthritis care & research, v. 71, n. 1, p. 71-79, 2019.
VANHOUTTE, Frédéric et al. Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK‐1 inhibitor, after short‐term treatment of rheumatoid arthritis: results of two randomized phase IIa trials. Arthritis & Rheumatology, v. 69, n. 10, p. 1949-1959, 2017.
VILLENEUVE, Edith; NAM, Jackie; EMERY, Paul. Critério de classificação da artrite reumatoide ACR-EULAR 2010. Rev. bras. reumatol, p. 481-483, 2010.
WEINBLATT, Michael. et al. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Arthritis Rheumatol 2018; 70: 49-59.
WESTHOVENS, René et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Annals of the rheumatic diseases, v. 80, n. 6, p. 727-738, 2021.
